Biopharma professionals will probably find decreasing employment opportunities this month and next even as layoffs continue, ...

If Eli Lilly's obesity pill orforglipron is approved and priced around $200 per month, analysts at Truist predict patients ...

Winrevair yielded significant and meaningful clinical benefits for patients with combined post- and precapillary pulmonary ...

A spokesperson for the FDA said the agency is “considering a wide range of options to support American innovation." ...

Within five business days, Alkermes can negotiate with Avadel to amend its original takeover offer to beat Lundbeck.

Merck has made a $9.2 billion play for Cidara, and there’s another bidding war afoot, this one for sleep biotech Avadel. Meanwhile, Rick Pazdur has taken the helm at CDER while tensions run high ...

In May, a BioSpace survey found that 56% of employed biopharma professionals are considering jobs outside the industry. Among the unemployed, that number jumps to 81%. In another pulse check, an ...

Communication must be viewed as more than the last step of the research process. It is the structure that makes scientific ...

Drug candidates don't usually move among Big Pharma, but these five biotechs helped facilitate such hand-offs, scooping up ...

Novo Nordisk goes "on the offensive" following Trump deal that also included rival Eli Lilly, putting an exclamation point on ...

The FDA approval of the siRNA drug Redemplo caps off a tumultuous 12 months for Arrowhead, whose partnership with Sarepta ...

A week into his tenure as head of the FDA’s Center for Drug Evaluation and Research, experts agree that Rick Pazdur is the ...